The presence of the BRAF mutation is associated with a significantly higher risk of dying of cancer-related causes, independently of other factors such as age, gender, PS, KRAS status, pathological finding, number of metastasis and metastatic sites, in agreement with other recent studies (Ogino et al, 2009; Tol et al, 2009; Bokemeyer et al, 2010; Fariña-Sarasqueta et al, 2010). This evidence concerns the gene KRAS and cancer.